During my recent conversation with Brett, I posed the question whether we could use SARS antibodies to combat SARS-CoV-2. As Brett explained, the SARS antibodies, when docked against a spike glycoprotein demonstrated poor binding, despite the similarities between the strains. Brett also pointed out SARS-CoV-2 binds 10-20x higher than SARS on our ACE2 receptor, presenting additional hurdles.
In short, no. The SARS antibodies are not cross-reactive with SARS-Cov-2. However, we can potentially use artificial intelligence to design variants of the existing SARS antibodies which are cross-reactive with SARS-CoV-2. Check out the clip below for additional insight and visualizations.